Evidence map›Paper›PMID 38902646›Full record

ArticleBMC endocrine disorders2024

Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight.

S Caprio, T Pilli, S Cantara, F Sestini, C Fioravanti, C Ciuoli, C Dalmiglio, A Corbo, M G Castagna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

S Caprio *Section of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
T Pilli *Section of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-1171-6384
S CantaraSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-5741-295X
F SestiniSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
C FioravantiSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
C CiuoliSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
C DalmiglioSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
A CorboSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy.
M G CastagnaSection of Endocrinology, Department of Medical, Surgical and Neurogical Sciences, University of Siena, Siena, Italy. mariagrazia.castagna@unisi.it.ORCID http://orcid.org/0000-0002-2457-1751

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAn increase of IGF-1 has been reported during therapy with dopamine agonists (DA) for prolactinomas; in such cases a correct diagnosis is pivotal to avoid an unnecessary reduction or withdrawal of DA, which are needed to maintain normal prolactin levels. This study was aimed to measure IGF-1 levels, at baseline and during follow-up, in a cohort of patients with prolactinoma, treated with cabergoline, stratified by body mass index.

methodsWe retrospectively enrolled 35 patients (15 F/20 M; age m ± SD, years: 43.4 ± 13.7) with prolactinoma (21 microadenomas and 14 macroadenomas) who were followed-up at the Endocrinology Unit, in Siena, and with available pituitary hormone assessment at baseline and during follow-up (m ± SD, years: 2.74 ± 0.55).

resultsIGF-1 increased in the whole cohort, but remaining within normal range, except two patients, in whom acromegaly was ruled out with oral glucose tolerance test. After dividing patients by weight, this trend was confirmed only in subjects with overweight and obesity (OV/OB) (p = 0.04). Interestingly, the reduction of prolactin levels was significantly greater in the OV/OB compared to normal-weight patients (median decrease of 97.5% versus 88.2%, p = 0.04).

conclusionsSince DA and normalization of prolactin are known to improve insulin sensitivity, we speculated they have favored the increase of IGF-1 in OV/OB. Our results should be confirmed and the hypothesis proven by further studies.

Indexed as

Dopamine AgonistsInsulin-Like Growth Factor IPituitary NeoplasmsProlactinomaAdultBody Mass IndexBody WeightCabergolineFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProlactinRetrospective StudiesCabergolineDopamine AgonistsIGF1 protein, humanInsulin-Like Growth Factor IProlactinBody mass indexDopamine-agonistsIGF-1Prolactinoma

Identifiers

PMID38902646
PMCPMC11188517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.